Glucosaminylmuramyl dipeptide acid (GMDP-A) modulates intracellular signaling pathways in natural killer cells [Глюкозаминилмурамилдипептид-кислота (ГМДП-А) модулирует внутриклеточные сигнальные пути натуральных киллерных клеток]

Introduction. Medicines developed as derivatives of muramyl peptides have been the subject of experimental and clinical studies for several decades. The intracellular NOD2- receptor responsible for the binding of muramyl dipeptide and its derivatives remains an attractive molecular target for the development of new drugs with a known mechanism of action. GMDP-A belongs to one of the NOD2-receptor ligands. In this study signaling mechanisms initiated by GMDP-A were characterized for the first time in natural killer (NK) cells. Material and methods. NK cells isolated by magnetic separation from peripheral blood of healthy donors were incubated with 10 μg/ml GMDP-A for 6 hours and 16 hours. The levels of genes expression were determined using the Illumina HumanHT-12v4 Expression BeadChip kit and Illumina iScan instrument (Illumina, USA). The data were statistically processed using an application software package (v 2011.1, Illumina). Results. It was found that GMDP-A enhanced the transcription of a number of genes associated with transduction of signals from receptors, thereby ensuring the maintenance of the functional activity of NK cells. GMDP-A induced the synthesis of transcripts of the MAPK signaling pathway, VAV2 signal mediators, the CRKL signal adapter, enhanced the synthesis of transcripts of the regulatory subunit 3 (γ) phosphoinositide-3-kinase and phospholipase C B1 genes that control phospholipid metabolism, activated the cells with defects in the cellular immunity link. GMDP-A significantly increases the expression level of the following key genes associated with the control of the mechanisms of direct and antibody-mediated cytotoxic activity of NK cells: CRKL, VAV2, ZAP70, RAP1A, PLCB1, FCGR3A, the MAPK family, IFNA1, TNFRSF9, TNFSF14. Conclusion. Experimental data justify the high potential of the GMDP-A to counteract altered recognition of the early stages of oncogenic and viral transformation by key cells of the innate immunity, the NK cells. © 2020 Meditsina Publishers. All rights reserved.

Guryanova S.V. 1, 2 , Gaponov A.M.3, 4 , Pisarev V.M.3, 4 , Yakushenko E.V.3 , Tutelyan A.V.5 , Alexandrov I.A.3 , Tsipandina E.V.4 , Kozlov I.G. 3, 6
Number of issue
  • 1 Shemyakin-Ovchinnikov Institute of Bioorganic, Chemistry of Russian Academy of Sciences, Ministry of Science and High Education of Russian Federation, Moscow, 117997, Russian Federation
  • 2 Peoples’ Friendship University of Russia, RUDN University, Medical Institute, Ministry of Science and High Education of Russian Federation, Moscow, 117198, Russian Federation
  • 3 Dmitry Rogachev National Medical Scientific Center of Pediatric Hematology, Oncology and Immunology, Ministry of Healthcare of Russian Federation, Moscow, 117198, Russian Federation
  • 4 Federal Scientific and Clinical Center of Intensive Care Medicine and Rehabilitation, Ministry of Healthcare of Russian Federation, Moscow, 141534, Russian Federation
  • 5 Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor), Moscow, 111123, Russian Federation
  • 6 Immanuel Kant Baltic Federal University, Ministry of Science and High Education of Russian Federation, Kaliningrad, 236041, Russian Federation
Anti-infection immunity; Anti-tumor immunity; Glucosaminyl muramyl dipeptide acid; Interferon; MAPK signaling pathway; Natural killer cells; Transcriptome
Date of creation
Date of change
Short link

Other records